KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Cash from Financing Activities: 2018-2025

Historic Cash from Financing Activities for Adaptive Biotechnologies (ADPT) over the last 7 years, with Sep 2025 value amounting to $1.7 million.

  • Adaptive Biotechnologies' Cash from Financing Activities rose 4110.00% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year increase of 4313.93%. This contributed to the annual value of $241,000 for FY2024, which is 89.27% down from last year.
  • As of Q3 2025, Adaptive Biotechnologies' Cash from Financing Activities stood at $1.7 million, which was up 4.60% from $1.6 million recorded in Q2 2025.
  • Adaptive Biotechnologies' Cash from Financing Activities' 5-year high stood at $125.5 million during Q3 2022, with a 5-year trough of $6,000 in Q4 2022.
  • Its 3-year average for Cash from Financing Activities is $1.0 million, with a median of $127,000 in 2024.
  • In the last 5 years, Adaptive Biotechnologies' Cash from Financing Activities plummeted by 99.99% in 2023 and then skyrocketed by 12,288.64% in 2025.
  • Quarterly analysis of 5 years shows Adaptive Biotechnologies' Cash from Financing Activities stood at $3.3 million in 2021, then crashed by 99.82% to $6,000 in 2022, then spiked by 1,350.00% to $87,000 in 2023, then surged by 45.98% to $127,000 in 2024, then soared by 4,110.00% to $1.7 million in 2025.
  • Its Cash from Financing Activities was $1.7 million in Q3 2025, compared to $1.6 million in Q2 2025 and $5.5 million in Q1 2025.